Motus Study: Findings Show Natural Supplement Ties with GLP-1
Tonum's latest human study found that Motus, our patented formula of 5 natural compounds, surpassed greater than 10% total weight loss, with 87% coming from fat versus lean muscle in a large human trial.
study methods
100 participants Ages 25–68, BMI ≥25 ½ tracked diet, exercise, and body fat percentage. Participants were grouped post hoc into behavioral categories based on diet and exercise habits. Results showed a clear dose-response relationship, with greater lifestyle adherence amplifying the supplement’s effects:
Category 1
14.83% weight loss (healthy diet + regular exercise 4+ times per week)
Category 2
Category 2: 10.02% weight loss (average diet + exercise 2–3 times per week)
Category 3
Category 3: 8.92% weight loss (average diet + no exercise)
Category 4
7.69% weight loss (poor diet + no exercise)
results & findings
40 participants who took Motus daily across the 24-week extension phase, average total body weight loss rose to 10.4%, with 87% of that loss coming from fat rather than lean mass. No major or long-lasting side effects were reported.
Shawna
weight before Motus: 238 lbs
weight after Motus: 203.6 lbs
Dave
weight before Motus: 231 lbs
weight after Motus: 192 lbs
Kim
weight before Motus: 165 lbs
weight after Motus: 142.8 lbs
how can you obtain similar results?
Pairing Motus with small, consistent changes can supercharge your results:
move more
Take the stairs, park further away, or call a friend for a walk – small movements add up!
follow the 80/20 rule
Eat nutrient-dense foods 80% of the time while allowing flexibility for balance.
switch up your workouts
Keep your body guessing with a mix of strength training, cardio, and fun activities like hiking or dancing.
Stay hydrated
Proper hydration supports digestion and fat metabolism – aim for at least 64oz of water daily.
By aligning with people’s natural lifestyles, Motus has the potential to fill a major gap in weight management—providing an effective, safe, and accessible option for the millions seeking alternatives to injectable drugs.
Study details
Full methodology, results and limitations of the 26-week human study of MOTUS, presented as a scientific poster at ObesityWeek.
| Study design | Open-label, single-arm human study. All participants received MOTUS; there was no placebo group and no blinding. |
|---|---|
| Participants | 100 adults, ages 25 to 68, BMI 25 or higher |
| Duration | Six months (26 weeks). Results were reported at 12 weeks for all participants and after the 24-week extension phase for those who continued, per the official announcement. |
| Intervention | MOTUS taken daily. No prescribed caloric restriction and no prescribed exercise programme. |
| Measured | Total body weight, body fat percentage, and self-reported diet and exercise habits |
| Sponsor | Tonum Health, in collaboration with Duke-affiliated researchers |
| Presented | Scientific poster, ObesityWeek |
| Publication status | Not yet published in a peer-reviewed journal |
Results
- Across all 100 participants, average total body weight loss was 5.1% at 12 weeks.
- Among the 40 participants who continued taking MOTUS daily through the 24-week extension phase, average total body weight loss rose to 10.4%, with 87% of the loss coming from fat rather than lean mass.
- A clear dose-response pattern appeared when participants were grouped after the fact by lifestyle habits:
- 14.83% average loss with a healthy diet and exercise 4 or more times per week
- 10.02% with an average diet and exercise 2 to 3 times per week
- 8.92% with an average diet and no exercise
- 7.69% with a poor diet and no exercise
- No major or long-lasting side effects were reported.
How to read these results
Limitations, stated plainly.
- The study was open-label with no placebo group, so some of the effect may come from participation itself rather than the supplement.
- Diet and exercise habits were self-reported, and the four behaviour groups were formed after the data was collected, not assigned in advance.
- The study was funded by Tonum Health, the maker of MOTUS.
- It has not yet been peer reviewed or published in a journal.
- These are study results, not a promise. Individual results vary, and MOTUS is not a substitute for prescribed medication.
Authors and poster
Nick Moore, PhD (Chief Scientific Officer, Tonum Health), Lance Converse, and Mark Brosso.
View and download the ObesityWeek poster, the full-resolution version of the data presented above.
Read the official study announcement, the press release as issued.
How to cite this study
Media and research enquiries: Tonum press room. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Second study: MOTUS alongside a GLP-1 receptor agonist
A separate preclinical study was carried out by researchers at the Duke Molecular Physiology Institute, Duke University, and presented as a scientific poster at ObesityWeek.
| Title | A Nutraceutical Intervention Adds to the Weight Loss Effects of a GLP-1R Agonist |
|---|---|
| Authors | Marshall Paisley, Danielle C. Leander, Jonathan E. Campbell — Duke Molecular Physiology Institute, Duke University, Durham, NC, USA |
| Model | Preclinical, rodent |
| Question | Whether the MOTUS nutraceutical adds to the weight-loss effect of a GLP-1 receptor agonist, and what happens after the agonist is stopped |
| Presented | Scientific poster, ObesityWeek |
| Publication status | Not yet published in a peer-reviewed journal |
What this does and does not show. This was a rodent study, not a human trial. Preclinical results do not transfer directly to people, and nothing here means MOTUS should be combined with, or substituted for, a prescription GLP-1 medication. If you take a GLP-1 medication, talk to your doctor before adding any supplement.
View and download the GLP-1 poster · Read our honest guide to natural GLP-1 alternatives